{"pmid":32383276,"title":"Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.","text":["Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.","Br J Clin Pharmacol","Eskazan, Ahmet Emre","32383276"],"journal":"Br J Clin Pharmacol","authors":["Eskazan, Ahmet Emre"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383276","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bcp.14353","keywords":["covid-19","chronic myeloid leukemia","qtc prolongation","sars-cov-2","drug-drug interaction","tyrosine kinase inhibitor"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666419683325116416,"score":9.490897,"similar":[{"pmid":32503877,"title":"Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.","text":["Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.","Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off-label to 19 patients hospitalized with severe COVID-19 (11 on supplemental oxygen; 8 on mechanical ventilation), 18 of whom had increasing oxygen requirements at baseline. Over a 10-14 day treatment course, acalabrutinib improved oxygenation in a majority of patients, often within 1-3 days, and had no discernable toxicity. Measures of inflammation - C-reactive protein and IL-6 - normalized quickly in most patients, as did lymphopenia, in correlation with improved oxygenation. At the end of acalabrutinib treatment, 8/11 (72.7%) patients in the supplemental oxygen cohort had been discharged on room air, and 4/8 (50%) patients in the mechanical ventilation cohort had been successfully extubated, with 2/8 (25%) discharged on room air. Ex vivo analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production in blood monocytes from patients with severe COVID-19 compared with blood monocytes from healthy volunteers. These results suggest that targeting excessive host inflammation with a BTK inhibitor is a therapeutic strategy in severe COVID-19 and has led to a confirmatory international prospective randomized controlled clinical trial.","Sci Immunol","Roschewski, Mark","Lionakis, Michail S","Sharman, Jeff P","Roswarski, Joseph","Goy, Andre","Monticelli, M Andrew","Roshon, Michael","Wrzesinski, Stephen H","Desai, Jigar V","Zarakas, Marissa A","Collen, Jacob","Rose, Keith","Hamdy, Ahmed","Izumi, Raquel","Wright, George W","Chung, Kevin K","Baselga, Jose","Staudt, Louis M","Wilson, Wyndham H","32503877"],"abstract":["Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off-label to 19 patients hospitalized with severe COVID-19 (11 on supplemental oxygen; 8 on mechanical ventilation), 18 of whom had increasing oxygen requirements at baseline. Over a 10-14 day treatment course, acalabrutinib improved oxygenation in a majority of patients, often within 1-3 days, and had no discernable toxicity. Measures of inflammation - C-reactive protein and IL-6 - normalized quickly in most patients, as did lymphopenia, in correlation with improved oxygenation. At the end of acalabrutinib treatment, 8/11 (72.7%) patients in the supplemental oxygen cohort had been discharged on room air, and 4/8 (50%) patients in the mechanical ventilation cohort had been successfully extubated, with 2/8 (25%) discharged on room air. Ex vivo analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production in blood monocytes from patients with severe COVID-19 compared with blood monocytes from healthy volunteers. These results suggest that targeting excessive host inflammation with a BTK inhibitor is a therapeutic strategy in severe COVID-19 and has led to a confirmatory international prospective randomized controlled clinical trial."],"journal":"Sci Immunol","authors":["Roschewski, Mark","Lionakis, Michail S","Sharman, Jeff P","Roswarski, Joseph","Goy, Andre","Monticelli, M Andrew","Roshon, Michael","Wrzesinski, Stephen H","Desai, Jigar V","Zarakas, Marissa A","Collen, Jacob","Rose, Keith","Hamdy, Ahmed","Izumi, Raquel","Wright, George W","Chung, Kevin K","Baselga, Jose","Staudt, Louis M","Wilson, Wyndham H"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503877","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1126/sciimmunol.abd0110","locations":["Bruton"],"e_drugs":["acalabrutinib"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892488360787968,"score":86.855194},{"pmid":32395220,"pmcid":"PMC7202347","title":"SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.","text":["SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.","Mediterr J Hematol Infect Dis","Abruzzese, Elisabetta","Luciano, Luigiana","D'Agostino, Francesco","Trawinska, Malgorzata Monika","Pane, Fabrizio","De Fabritiis, Paolo","32395220"],"journal":"Mediterr J Hematol Infect Dis","authors":["Abruzzese, Elisabetta","Luciano, Luigiana","D'Agostino, Francesco","Trawinska, Malgorzata Monika","Pane, Fabrizio","De Fabritiis, Paolo"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395220","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.4084/MJHID.2020.031","keywords":["abl","cml","covid-19","sars-cov-2","tki"],"link_comment_for":"30671212","locations":["Viral Infection"],"topics":["Case Report"],"weight":1,"_version_":1666627827858931714,"score":80.518875},{"pmid":32399097,"pmcid":"PMC7212214","title":"Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.","text":["Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.","Arch Med Sci","Nabavi, Seyed Fazel","Habtemariam, Solomon","Clementi, Emilio","Berindan-Neagoe, Ioana","Cismaru, Cosmin Andrei","Rasekhian, Mahsa","Banach, Maciej","Izadi, Morteza","Bagheri, Mahdi","Bagheri, Mohammad Sadegh","Nabavi, Seyed Mohammad","32399097"],"journal":"Arch Med Sci","authors":["Nabavi, Seyed Fazel","Habtemariam, Solomon","Clementi, Emilio","Berindan-Neagoe, Ioana","Cismaru, Cosmin Andrei","Rasekhian, Mahsa","Banach, Maciej","Izadi, Morteza","Bagheri, Mahdi","Bagheri, Mohammad Sadegh","Nabavi, Seyed Mohammad"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399097","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.5114/aoms.2020.94504","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666714494870487040,"score":71.94246},{"pmid":32409150,"title":"An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.","text":["An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.","BACKGROUND: Chloroquine or hydroxychloroquine (chloroquine) plus azithromycin is considered as therapy for COVID-19. With benefit evaluations underway, safety concerns due to potential additive effects on QTc prolongation should be addressed. OBJECTIVE: We compared risk of cardiac adverse events between combinations of chloroquine and azithromycin and chloroquine and amoxicillin. METHODS: We conducted a retrospective cohort study using the IBM MarketScan Commercial Claims and Medicare Supplemental Databases, 2005-2018. We included autoimmune disease patients aged >/=18 years initiating azithromycin or amoxicillin for >/=5 days during chloroquine treatment. Patients had continuous insurance coverage >/=6 months before combination use until 5 days thereafter or inpatient death. Two outcomes were sudden cardiac arrest/ventricular arrhythmias (SCA/VA) and cardiac symptoms. We followed patients for up to 5 days to estimate hazard ratios (HR). Covariates were adjusted using stabilized inverse probability treatment weighting. RESULTS: We identified two SVC/VA events among >145,000 combination users. The adjusted incidence of cardiac symptoms among azithromycin and amoxicillin users was 276 vs 254 per 10,000 person-years with an adjusted HR of 1.10 (95%CI, 0.62-1.95). CONCLUSION: Combination use of chloroquine and azithromycin at routine doses did not show pronounced increases in arrhythmias in this real-world population, though small sample size and outcome rates limit conclusions.","Res Social Adm Pharm","Vouri, Scott M","Thai, Thuy N","Winterstein, Almut G","32409150"],"abstract":["BACKGROUND: Chloroquine or hydroxychloroquine (chloroquine) plus azithromycin is considered as therapy for COVID-19. With benefit evaluations underway, safety concerns due to potential additive effects on QTc prolongation should be addressed. OBJECTIVE: We compared risk of cardiac adverse events between combinations of chloroquine and azithromycin and chloroquine and amoxicillin. METHODS: We conducted a retrospective cohort study using the IBM MarketScan Commercial Claims and Medicare Supplemental Databases, 2005-2018. We included autoimmune disease patients aged >/=18 years initiating azithromycin or amoxicillin for >/=5 days during chloroquine treatment. Patients had continuous insurance coverage >/=6 months before combination use until 5 days thereafter or inpatient death. Two outcomes were sudden cardiac arrest/ventricular arrhythmias (SCA/VA) and cardiac symptoms. We followed patients for up to 5 days to estimate hazard ratios (HR). Covariates were adjusted using stabilized inverse probability treatment weighting. RESULTS: We identified two SVC/VA events among >145,000 combination users. The adjusted incidence of cardiac symptoms among azithromycin and amoxicillin users was 276 vs 254 per 10,000 person-years with an adjusted HR of 1.10 (95%CI, 0.62-1.95). CONCLUSION: Combination use of chloroquine and azithromycin at routine doses did not show pronounced increases in arrhythmias in this real-world population, though small sample size and outcome rates limit conclusions."],"journal":"Res Social Adm Pharm","authors":["Vouri, Scott M","Thai, Thuy N","Winterstein, Almut G"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32409150","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.sapharm.2020.04.031","keywords":["covid19","cardiac events","chloroquine","hydroxychloroquine","qtc prolongation"],"locations":["amoxicillin"],"e_drugs":["Chloroquine","Amoxicillin","Hydroxychloroquine","Azithromycin"],"topics":["Treatment"],"weight":1,"_version_":1666897319263469568,"score":65.23173},{"pmid":32339701,"pmcid":"PMC7195037","title":"Potential role of Janus kinase inhibitors in COVID-19.","text":["Potential role of Janus kinase inhibitors in COVID-19.","J Am Acad Dermatol","Napolitano, Maddalena","Fabbrocini, Gabriella","Patruno, Cataldo","32339701"],"journal":"J Am Acad Dermatol","authors":["Napolitano, Maddalena","Fabbrocini, Gabriella","Patruno, Cataldo"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339701","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jaad.2020.04.098","keywords":["covid-19","jak inhibitors","atopic dermatitis","baricitinib","infection","upadacitinib"],"locations":["Janus"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494227972098,"score":64.5405}]}